Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-30T20:25:36.404Z Has data issue: false hasContentIssue false

The developing role of pharmacogenetics in psychiatry

Published online by Cambridge University Press:  18 September 2015

Extract

A great interindividual variability exists in biological response to drugs. This variability is partly attributable to pharmacodynamic factors (drug - receptor interactions) and partly to pharmacokinetic factors. Drugs can be eliminated from the body by renal clearance, metabolism or both. Although every tissue has some ability to metabolise xenobiotics like drugs, the liver is the principal organ of biotransformation. Major metabolising enzymes are the cytochrome-P450 mono-oxygenases, epoxide hydrolase, glucuronosyl-transferase, acetyl-transferase, sulfo-transferase and xanthine oxidase. Some of these enzymes display in a subset of subjects a ‘normal’ activity and in another subset of subjects a reduced or a greatly increased activity. This altered activity may be genetically determined and is then called genetic polymorphism. Clinically relevant metabolic differences traditionally have been defined by their genotypie expression such as ‘poor’ and ‘extensive’ metaboliser. The recent developments of powerful methods for DNA (or genomic) analysis portends a revolutionary expansion of our understanding of physiology as well as pathology. Pharmacogenetics is the study of genetic variation underlying differential response to drugs. Genotyping may become a useful tool in optimising drug treatment. Another part of the genetic research is directed towards the discovery of genetic alterations leading to diseases. Once identified, these genetic alterations can become targets for drug treatment (e.g. gene therapy). Pharmaco-genomics applies the large-scale systematic approaches of genomics to speed the discovery of drug response markers, whether they act at the level of the drug target, drug metabolism or disease pathway. Table I gives some examples of genetic alterations that are identified together with their effects. Some of these examples will be briefly discussed here.

Type
Research Article
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Recommended literature

Arranz, MJ, Munro, J, Sham, P, et al.Meta-analysis of studies on genetic variation in 5HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93–9.CrossRefGoogle ScholarPubMed
Brøsen, K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18: 393–6.CrossRefGoogle ScholarPubMed
Kirov, G, Murphy, KC, Arranz, MJ, et al.Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiat 1998; 3: 342–5.CrossRefGoogle ScholarPubMed
Kleyn, PW, Vesell, ES. Genetic variation as a guide to drug development. Science 1998; 281: 1820–1.CrossRefGoogle ScholarPubMed
Meyer, UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharmac 1996; 24: 449–59.CrossRefGoogle ScholarPubMed
Spielberg, SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996;24:509–19.CrossRefGoogle ScholarPubMed
Touw, DJ. Genetische aspecten bij het metabolisme van geneesmiddelen. Pharm Weekbl 1998; 133: 1679–84.Google Scholar
Touw, DJ, Verhoeven, WMA, Noten, JBGM. Het cytochroom P450 enzymsysteem: wat is de relevantie voor de praktijk? Deel I, de isoenzymes Acta neuropsychiat 1998; 10: 3442.CrossRefGoogle ScholarPubMed
Touw, DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metab Drug Interact 1997; 14: 5582.Google ScholarPubMed